Status and phase
Conditions
Treatments
About
To prove that the efficacy and safety of 'NK group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(RFA or operation) for hepatocellular carcinoma in China.
Full description
No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma receiving curative treatment.We investigated whether injections of NK cells prolongs recurrence-free survival of patients after curative therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups
Loading...
Central trial contact
Cheng Qian, MD, PhD; Zhi Yang, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal